NCT05064085: Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with any previous treatment of a PD-1 or PD-L1 inhibitor, including cemiplimab; Patients with untreated unstable brain metastasis; Patients with leptomeningeal disease

Comments are closed.

Up ↑